Improving and harmonising the Summary of Product Characteristics and the conditions for use of old antibacterials

current use of legal tools and future perspectives

Best use of medicines legislation to bring new antibiotics to patients and combat the resistance problem – EMA, London 8 November 2013

Presented by: Dr. Radu Botgros
Scientific Administrator-Office of Anti-infectives and Vaccines
One European system: two procedures for approving medicines

Centralised procedure

Mutual recognition and decentralised procedure

Improving and harmonising the Summary of Product Characteristics and the conditions for use of old antibacterials
Summary of product characteristics (SmPC)

• Legal document approved as a part of the marketing authorisation

• Basis of information for healthcare professionals on how to use a medicine

• Information updated throughout the lifecycle of the product
Harmonisation of SmPCs of old antibacterials across the EU

Referral procedures

- Reg (EC) 726/2004
- Dir 2001/83/EC
- New PhV legislation:
  - Reg (EU) 1235/2010
  - Dir 2010/84/EU

- procedures used to resolve certain issues (such as concerns over the safety or benefit-risk balance) of a medicine/class of medicines and to harmonise SmPCs where necessary

- Different types:
  - “art 30” and “art 31” referrals of particular interest
  - “art 5(3)” for major tuberculostatics, art 107 (moxifloxacin)

Other procedures: e.g. art 45 of the Paediatric Regulation, etc.

Improving and harmonising the Summary of Product Characteristics and the conditions for use of old antibacterials
Article 30 of Directive 2001/83/EC ("Divergent decision referral")

- triggered when Member States have adopted different decisions over the years for some medicines (e.g. different indications, contraindications or posology) and there is a need to **harmonise** across the EU.

- article 30(1) referral: divergent decisions adopted by MSs concerning the authorisation, suspension or withdrawal of a particular medicinal product (e.g. different indications, contraindications or posology)

  - triggered by the EC, a MS, a MAH/Applicant.

- article 30(2) referral: initiated for the same reasons when the medicinal product is on the list of the coordination group.
Article 30 triggered by European Commission

**Proactive harmonisation**

- Member States propose each year products for SmPC harmonisation
- CMD(h) lays down list and forwards to Commission
- Commission or MS, in agreement with EMA, may refer the product

**CMD(h) subgroup (with participation of CMD(h), CHMP, EC, EMA) on SmPC harmonisation**

→ Mandate and criteria for selection agreed and published
Article 30 triggered by the Marketing Authorisation Holder

- voluntary triggering of a procedure by the MAH, to harmonise the Product Information of own products.

- the MAH defines the scope of the referral (which presentations, which indications to include).

- the procedure starts with a proposal for a harmonised Product Information submitted by the MAH, to be assessed by the CHMP.

Improving and harmonising the Summary of Product Characteristics and the conditions for use of old antibacterials
### Completed art. 30 referrals for antibacterials

<table>
<thead>
<tr>
<th>Approved name</th>
<th>INN</th>
<th>Associated names</th>
<th>Opinion date</th>
<th>EC decision date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Augmentin</td>
<td>amoxicillin+clavulanic acid</td>
<td></td>
<td>19.01.2009</td>
<td>19.10.2009</td>
</tr>
<tr>
<td>Ciprofloxacin Bayer</td>
<td>ciprofloxacin</td>
<td></td>
<td>24.07.2008</td>
<td>07.10.2008</td>
</tr>
<tr>
<td>Tazocin</td>
<td>piperacillin/tazobactam</td>
<td>Tazobac, Tazocel, Tazonac</td>
<td>21.10.2010</td>
<td>21.02.2011</td>
</tr>
<tr>
<td>Fortum</td>
<td>ceftazidime</td>
<td>Cefortam, Glazidin, Panzim, Solvetan</td>
<td>21.10.2010</td>
<td>13.01.2011</td>
</tr>
<tr>
<td>Tienam</td>
<td>imipenem/cilastatin</td>
<td>Conet, Imipem, Primaxin, Tenacid, Zienam</td>
<td>06.12.2010</td>
<td>10.03.2011</td>
</tr>
<tr>
<td>Tavanic</td>
<td>levofloxacin</td>
<td>Tavanic and associated names</td>
<td>24.05.2012</td>
<td>31.07.2012</td>
</tr>
<tr>
<td>Zinacef</td>
<td>cefuroxime sodium</td>
<td>Curocef, Curoxim, Curoxim Monovial, Curoxime,</td>
<td>24.05.2012</td>
<td>10.09.2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Curoxime, Zinnat, Zinocep, Zinocep Vena</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinnat</td>
<td>cefuroxime axetil</td>
<td>Cefuroxima Solasma, Cefuroxima Allen, Cefuroxima</td>
<td>24.05.2012</td>
<td>23.08.2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Duncan, Elobact, Nivador, Oraxim, Selan, Tilexim,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zinadel, Zipos, Zoref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Targocid</td>
<td>teicoplanin</td>
<td>Targocid, Teicomid</td>
<td>30.05.2013</td>
<td>pending</td>
</tr>
</tbody>
</table>

Improving and harmonising the Summary of Product Characteristics and the conditions for use of old antibacterials
Example of finalised harmonisation: meropenem

Harmonisation involves:

- review of evidence to support efficacy,
- replacement of older broad indications that are no longer used with more specific indications based on the available data and
- a review of the posology in all age groups.
- Section 5.1 (describing the microbiological properties) is also updated.

Areas harmonised:

- 4.1 therapeutic indications
- 4.2 posology and method of administration
- 4.3 contraindications
- 4.4 special warnings and precautions for use

Improving and harmonising the Summary of Product Characteristics and the conditions for use of old antibacterials
Article 31 of Directive 2001/83/EC ("community interest referral")

- triggered when the public health interest of the Community is involved, following concerns relating to the quality, safety or efficacy of a medicine/class of medicines which is/are on the market in the EU.
  - triggered by the EC, a MS, a MAH/Applicant.
  - Scope can relate to a range of products or a therapeutic class.
  - Referral type used for norfloxacin (completed) and colistin (ongoing)

Improving and harmonising the Summary of Product Characteristics and the conditions for use of old antibacterials
Limitations of regulatory actions

- Number of procedures per year limited by the capacity of the EU regulatory network
- Different patterns of prevalence and resistance of infectious diseases
- Differences in clinical practice and use of certain antibiotics
- Harmonisation and modernisation of SmPC cannot and should not replace treatment guidelines and antibiotic stewardship
CHMP/IDWP proposal for prioritisation of harmonisation of old antibacterials SmPCs to CMDh (2011)

<table>
<thead>
<tr>
<th>1. vancomycin</th>
<th>9. erithromycin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. amoxicillin</td>
<td>10. clindamycin</td>
</tr>
<tr>
<td>3. ampicillin</td>
<td>11. rifampicin</td>
</tr>
<tr>
<td>4. phenoxy methylpenicillin</td>
<td>12. gentamicin</td>
</tr>
<tr>
<td>5. benzylpenicillin</td>
<td>13. tobramycin</td>
</tr>
<tr>
<td>6. cefotaxime</td>
<td>14. amikacin</td>
</tr>
<tr>
<td>7. azithromycin</td>
<td>15. trimethoprim/sulphamethoxazole</td>
</tr>
<tr>
<td>8. clarithromycin</td>
<td>16. metronidazole</td>
</tr>
<tr>
<td></td>
<td>17. doxycycline</td>
</tr>
</tbody>
</table>

Improving and harmonising the Summary of Product Characteristics and the conditions for use of old antibacterials
Conclusions

Improvement of SmPCs of „old“ antibacterials:

• Important regulatory tool which ensures the provision of the same updated information to all EU healthcare professionals

• Opportunity to modernise the product information

• Should not replace treatment guidelines/antibiotic stewardship

• Prioritisation of the exercise is key, in view of the limited resources.

• Harmonisation of SmPCs by referrals should continue and should be strengthened
BACK-UP SLIDES

Improving and harmonising the Summary of Product Characteristics and the conditions for use of old antibiotics
Article 30

1. If two or more applications submitted in accordance with Articles 8, 10, 10a, 10b, 10c and 11 have been made for marketing authorisation for a particular medicinal product, and if Member States have adopted divergent decisions concerning the authorisation of the medicinal product or its suspension or revocation, a Member State, the Commission or the applicant or the marketing authorisation holder may refer the matter to the Committee for Medicinal Products for Human Use, hereinafter referred to as “the Committee”, for the application of the procedure laid down in Articles 32, 33 and 34.
Article 30

2. In order to promote harmonisation of authorisations for medicinal products authorised in the Community, Member States shall, each year, forward to the coordination group a list of medicinal products for which a harmonised summary of product characteristics should be drawn up. The coordination group shall lay down a list taking into account the proposals from all Member States and shall forward this list to the Commission. The Commission or a Member State, in agreement with the Agency and taking into account the views of interested parties, may refer these products to the Committee in accordance with paragraph 1.
Article 31

1. The Member States or the Commission or the applicant or the marketing authorisation holder shall, in specific cases where the interests of the Community are involved, refer the matter to the Committee for application of the procedure laid down in Articles 32, 33 and 34 before any decision is reached on a request for a marketing authorisation or on the suspension or revocation of an authorisation, or on any other variation to the terms of a marketing authorisation which appears necessary, in particular to take account of the information collected in accordance with Title IX. The Member State concerned or the Commission shall clearly identify the question which is referred to the Committee for consideration and shall inform the applicant or the marketing authorisation holder. The Member States and the applicant or the marketing authorisation holder shall supply the Committee with all available information relating to the matter in question.
Article 31

2. Where the referral to the Committee concerns a range of medicinal products or a therapeutic class, the Agency may limit the procedure to certain specific parts of the authorisation. In that event, Article 35 shall apply to those medicinal products only if they were covered by the authorisation procedures referred to in this Chapter.